Johnson & Johnson is navigating critical financial terrain as it prepares for earnings reports linked to its Covid-19 vaccine revenue, amid intensifying market competition. With an anticipated boost in valuation from analysts, including a notable Morgan Stanley upgrade spurred by record sales surpassing $100 billion, the company is also reassessing its focus, having recently withdrawn from RSV vaccine development. Meanwhile, broader market dynamics show S&P 500 companies largely exceeding expectations, although Pfizer struggles with earnings challenges, reflecting the ongoing impact of vaccine revenues on major pharmaceutical firms.
Click a month on the chart to update the report below.
